Shanghai Unibest Pharmaceutical Technology Co., Ltd.
Reactive functional monomer platform · global pharma trade
Founded in February 2022 and based in the Nanhui Industrial Park, Pudong, Shanghai, Shanghai Unibest Pharmaceutical Technology is a innovation-driven company specialized in organic synthesis. It is the core operating entity of the Unibest Pharma platform. Built on three technology platforms — chiral synthesis, efficient catalysis and green chemistry — the company covers reactive functional monomers, pharmaceutical intermediates and premium hair-dye intermediates, and operates the Unibest Pharma platform (www.unibest.cc) for global pharma trade and registration services.
Company registry
| Registered name | Shanghai Unibest Pharmaceutical Technology Co., Ltd. |
| USCC | 91310115MA7H2AAK07 |
| Legal representative | Liu Jia (registered legal representative) |
| Founded | 2022-02-28 |
| Registered capital | RMB 6.6667 million |
| Registered address | Room 201, Floor 2, Building 1, No. 233 Yuanzhong Road, Huinan Town, Pudong, Shanghai |
| Status | Active (in operation) |
1,136 m² R&D and pilot facility (Shanghai) · production base in Xinji, Hebei
Licenses & qualifications
- National High-Tech Enterprise (Dec 2024)
- National SME of Science & Technology (Oct 2025)
- Shanghai "Specialized & Sophisticated" Enterprise (Mar 2026)
- Shanghai Pudong "Pearl Program" engineer project (Dec 2025)
- ISO 9001 / 14001 / 45001 certified (Jan 2025)
Business focus
Three technology platforms
Reactive functional monomer platform — one base, three tracks
Core design logic: polymerizable/reactive handles (C=C, –OH) combined with functional elements (Si, P) anchored via covalent bonds. Three tracks share one synthesis & QC platform, eliminating migration and precipitation of additive-type systems.
Dual routes of TMSPM (CAS 17096-07-0) and branched trisiloxanol; hydrophobic segments permanently anchored via C=C copolymerization / hydroxyl condensation, filling the gap as PFAS repellents phase out.
Amide-bond-linked dihydrogen phosphate esters with better hydrolytic stability than commercial ester-bond analogues, targeting aqueous lithium-ion battery binders — phosphate coordination improves cycling of LTO / silicon anodes.
Six polymerizable phosphorus monomers (M1–M6, P content 12.28%–15.88%) form a parametrized library; covalently anchored after copolymerization with no migration, targeting UL94 V-0 at 4%–10% loading for engineering plastics, copper clad laminates and coatings.
C=C copolymerization, hydroxyl condensation and phosphate coordination — three covalent anchoring mechanisms that additive-type systems can hardly cross.
Milestones
2023–2025 are actual results; 2026E and beyond are company planning targets, not commitments.
Founding team
Ph.D. in medicinal chemistry (Second Military Medical University) · postdoc at Zhejiang University. Former head of synthesis / GM at Maosheng Kanghui, leading industrialization of innovative-drug and premium generics intermediates; track record includes eribulin intermediates, Xaban-class APIs and fluorine-free water-repellent monomers.
Ph.D. in organic chemistry (Zhejiang University), heterocycle synthesis methodology. Former section chief of process integration at Hehui Optoelectronics, leading OLED flexible encapsulation mass production; two Org. Lett. papers (IF 6.732); leads photoresist monomer R&D.